Clinical trial
Dexanabinol in Severe Traumatic Brain Injury
NCT00129857 · Pharmos, Industry · Completed
Key facts
| NCT number | NCT00129857 |
|---|---|
| Title | Dexanabinol in Severe Traumatic Brain Injury |
| Official title | Efficacy and Safety Evaluation of a Single Intravenous Dose of Dexanabinol in Patients Suffering From Severe Traumatic Brain Injury |
| Lead sponsor | Pharmos, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Traumatic Brain Injury |
| Intervention type | Drug |
| Interventions | Dexanabinol |
| Enrollment | 860 |
| Start date | Jan 1, 2001 |
| Completion | Sep 1, 2004 |
| First posted | Aug 12, 2005 |
| Last update posted | May 5, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: